IMFINZI Study in Patients With Extensive Stage Small Cell Lung Cancer

AstraZeneca

Status: Completed

Conditions: Carcinoma, Small Cell

Study type: Observational

Funder types: Industry

Identifiers

NCT04854590

D419QC00006

Details and patient eligibility

About

To capture safety(FN) when IMF is administered to patients with extensive stage small cell lung cancer in clinical practice after launch

Full description

To capture the onset (incidence, severity, intervention, outcome, and others) of febrile neutropenia in patients with extensive stage small cell lung cancer who receive durvalumab in combination with platinum agent and etoposide under the actual use.

Enrollment: 248 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

-Patients with extensive stage small cell lung cancer who are receiving the product in combination with platinum agent and etoposide.

Exclusion criteria

-Patients who have no treatment history with the product (i.e.,durvalumab)